COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference Post published:March 2, 2023 Post category:Press Release
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights Post published:February 28, 2023 Post category:Press Release
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023 Post published:February 24, 2023 Post category:Press Release
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP Post published:December 8, 2022 Post category:Press Release
COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference Post published:November 28, 2022 Post category:Press Release
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights Post published:November 4, 2022 Post category:Press Release
Analysis: COMPASS Pathways Phase 2b Psilocybin Trial Published in NEJM Post published:November 2, 2022 Post category:Analysis
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022 Post published:October 28, 2022 Post category:Press Release
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day Post published:October 12, 2022 Post category:Press Release
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022 Post published:October 6, 2022 Post category:Press Release